| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lung Transplantation | 56 | 2021 | 367 | 7.680 |
Why?
|
| Graft Rejection | 28 | 2025 | 1127 | 3.390 |
Why?
|
| Immunosuppressive Agents | 18 | 2014 | 997 | 2.510 |
Why?
|
| Bronchiolitis Obliterans | 12 | 2019 | 37 | 2.200 |
Why?
|
| Primary Graft Dysfunction | 17 | 2018 | 44 | 1.630 |
Why?
|
| Sirolimus | 5 | 2014 | 177 | 1.540 |
Why?
|
| Lung | 12 | 2022 | 1380 | 1.070 |
Why?
|
| Lung Diseases, Interstitial | 6 | 2022 | 292 | 1.050 |
Why?
|
| Lung Diseases | 10 | 2018 | 288 | 0.930 |
Why?
|
| Postoperative Complications | 11 | 2025 | 2603 | 0.920 |
Why?
|
| Biomarkers | 16 | 2025 | 1931 | 0.830 |
Why?
|
| Idiopathic Pulmonary Fibrosis | 8 | 2022 | 210 | 0.830 |
Why?
|
| Tacrolimus | 4 | 2010 | 373 | 0.760 |
Why?
|
| Cytomegalovirus Infections | 4 | 2013 | 155 | 0.740 |
Why?
|
| Tissue Donors | 7 | 2025 | 542 | 0.720 |
Why?
|
| Frailty | 2 | 2020 | 94 | 0.710 |
Why?
|
| Sarcopenia | 1 | 2020 | 20 | 0.660 |
Why?
|
| Patient Selection | 4 | 2021 | 708 | 0.640 |
Why?
|
| Hypertension, Pulmonary | 4 | 2018 | 383 | 0.620 |
Why?
|
| Prospective Studies | 24 | 2025 | 4690 | 0.610 |
Why?
|
| Cell-Free Nucleic Acids | 3 | 2025 | 94 | 0.610 |
Why?
|
| Scleroderma, Systemic | 1 | 2018 | 59 | 0.550 |
Why?
|
| Biopsy | 7 | 2024 | 1210 | 0.540 |
Why?
|
| Middle Aged | 46 | 2025 | 28299 | 0.500 |
Why?
|
| Bronchoscopy | 7 | 2022 | 175 | 0.490 |
Why?
|
| Reperfusion Injury | 3 | 2016 | 148 | 0.490 |
Why?
|
| Humans | 80 | 2025 | 95992 | 0.470 |
Why?
|
| Transplantation | 2 | 2006 | 38 | 0.460 |
Why?
|
| Cytomegalovirus | 4 | 2006 | 89 | 0.460 |
Why?
|
| Bronchoalveolar Lavage Fluid | 4 | 2016 | 133 | 0.450 |
Why?
|
| Graft Survival | 10 | 2025 | 942 | 0.440 |
Why?
|
| Male | 50 | 2025 | 45792 | 0.440 |
Why?
|
| HLA-G Antigens | 1 | 2014 | 52 | 0.420 |
Why?
|
| Azathioprine | 2 | 2010 | 125 | 0.390 |
Why?
|
| Female | 48 | 2025 | 49980 | 0.390 |
Why?
|
| Macrophages, Alveolar | 3 | 2018 | 66 | 0.380 |
Why?
|
| Genomics | 4 | 2022 | 857 | 0.360 |
Why?
|
| Time Factors | 13 | 2024 | 5593 | 0.320 |
Why?
|
| Adult | 32 | 2025 | 28636 | 0.300 |
Why?
|
| Follow-Up Studies | 13 | 2025 | 3922 | 0.300 |
Why?
|
| Clinical Decision-Making | 2 | 2022 | 296 | 0.290 |
Why?
|
| Microbiota | 1 | 2014 | 425 | 0.280 |
Why?
|
| Kidney Transplantation | 2 | 2025 | 882 | 0.280 |
Why?
|
| Venous Thromboembolism | 1 | 2010 | 171 | 0.270 |
Why?
|
| Aged | 17 | 2025 | 20927 | 0.260 |
Why?
|
| Risk Factors | 12 | 2025 | 5992 | 0.260 |
Why?
|
| Interleukin-15 | 1 | 2007 | 76 | 0.250 |
Why?
|
| Interleukin-2 | 1 | 2007 | 246 | 0.240 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 6 | 2012 | 306 | 0.240 |
Why?
|
| Ganciclovir | 2 | 2002 | 52 | 0.230 |
Why?
|
| Syndrome | 3 | 2020 | 450 | 0.230 |
Why?
|
| Quality of Life | 2 | 2012 | 1816 | 0.230 |
Why?
|
| Drug Therapy, Combination | 4 | 2010 | 789 | 0.220 |
Why?
|
| Lung Neoplasms | 3 | 2022 | 2384 | 0.220 |
Why?
|
| Inflammation Mediators | 2 | 2018 | 161 | 0.220 |
Why?
|
| Base Sequence | 2 | 2006 | 2341 | 0.200 |
Why?
|
| Mycophenolic Acid | 1 | 2003 | 86 | 0.200 |
Why?
|
| Drug Monitoring | 3 | 2012 | 120 | 0.200 |
Why?
|
| Retrospective Studies | 13 | 2024 | 10307 | 0.200 |
Why?
|
| Gene Expression Profiling | 3 | 2018 | 1533 | 0.200 |
Why?
|
| Incidence | 5 | 2014 | 1723 | 0.190 |
Why?
|
| Uteroglobin | 2 | 2014 | 4 | 0.190 |
Why?
|
| Opportunistic Infections | 1 | 2002 | 60 | 0.190 |
Why?
|
| Heart Transplantation | 2 | 2025 | 816 | 0.180 |
Why?
|
| Serum Amyloid P-Component | 2 | 2012 | 5 | 0.180 |
Why?
|
| Prognosis | 7 | 2025 | 3993 | 0.180 |
Why?
|
| Pulmonologists | 1 | 2022 | 7 | 0.180 |
Why?
|
| Epithelial Cells | 2 | 2019 | 704 | 0.180 |
Why?
|
| Nucleic Acid Hybridization | 1 | 2001 | 241 | 0.170 |
Why?
|
| Organophosphonates | 1 | 2001 | 53 | 0.170 |
Why?
|
| United States | 10 | 2022 | 7785 | 0.170 |
Why?
|
| Cohort Studies | 9 | 2022 | 3115 | 0.170 |
Why?
|
| Kidney Failure, Chronic | 1 | 2025 | 432 | 0.170 |
Why?
|
| Nitric Oxide | 2 | 2000 | 281 | 0.170 |
Why?
|
| C-Reactive Protein | 2 | 2012 | 206 | 0.170 |
Why?
|
| Survival Rate | 7 | 2018 | 1978 | 0.170 |
Why?
|
| Viral Load | 1 | 2001 | 164 | 0.160 |
Why?
|
| Pulmonary Fibrosis | 2 | 2017 | 153 | 0.160 |
Why?
|
| Connective Tissue Diseases | 1 | 2021 | 75 | 0.160 |
Why?
|
| Aged, 80 and over | 6 | 2023 | 7224 | 0.160 |
Why?
|
| Respiration, Artificial | 3 | 2000 | 425 | 0.160 |
Why?
|
| Myositis | 1 | 2020 | 18 | 0.160 |
Why?
|
| Frail Elderly | 1 | 2020 | 92 | 0.160 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2023 | 258 | 0.160 |
Why?
|
| Smoking | 3 | 2022 | 651 | 0.150 |
Why?
|
| Acute Disease | 5 | 2014 | 859 | 0.150 |
Why?
|
| Solitary Pulmonary Nodule | 1 | 2020 | 139 | 0.150 |
Why?
|
| Organ Transplantation | 2 | 2018 | 298 | 0.150 |
Why?
|
| Enterococcus | 1 | 1999 | 35 | 0.150 |
Why?
|
| Forced Expiratory Volume | 2 | 2014 | 136 | 0.150 |
Why?
|
| Case-Control Studies | 7 | 2018 | 1962 | 0.150 |
Why?
|
| Bronchodilator Agents | 1 | 1999 | 70 | 0.140 |
Why?
|
| Vancomycin | 1 | 1999 | 75 | 0.140 |
Why?
|
| Polymorphism, Single Nucleotide | 3 | 2025 | 2495 | 0.140 |
Why?
|
| Predictive Value of Tests | 4 | 2024 | 1819 | 0.140 |
Why?
|
| Nasal Mucosa | 1 | 2018 | 196 | 0.140 |
Why?
|
| Immunoglobulin G | 3 | 2007 | 481 | 0.140 |
Why?
|
| Autoantibodies | 1 | 2019 | 281 | 0.140 |
Why?
|
| Sequence Analysis, RNA | 1 | 2019 | 255 | 0.130 |
Why?
|
| Cells, Cultured | 3 | 2019 | 2928 | 0.130 |
Why?
|
| Metformin | 1 | 2018 | 125 | 0.130 |
Why?
|
| Particulate Matter | 1 | 2018 | 124 | 0.130 |
Why?
|
| Alveolar Epithelial Cells | 1 | 2017 | 18 | 0.130 |
Why?
|
| Transplantation Immunology | 3 | 2011 | 83 | 0.130 |
Why?
|
| Air Pollution | 1 | 2018 | 107 | 0.130 |
Why?
|
| Respiratory Mucosa | 2 | 2022 | 90 | 0.130 |
Why?
|
| Sirtuin 3 | 1 | 2017 | 36 | 0.130 |
Why?
|
| Ventricular Dysfunction, Right | 1 | 1999 | 169 | 0.130 |
Why?
|
| Algorithms | 1 | 2025 | 2018 | 0.130 |
Why?
|
| Cause of Death | 1 | 2018 | 279 | 0.120 |
Why?
|
| Stem Cells | 1 | 2019 | 394 | 0.120 |
Why?
|
| Logistic Models | 6 | 2018 | 1273 | 0.120 |
Why?
|
| DNA, Mitochondrial | 1 | 2017 | 200 | 0.120 |
Why?
|
| Apoptosis | 2 | 2017 | 1756 | 0.120 |
Why?
|
| Up-Regulation | 1 | 2018 | 740 | 0.120 |
Why?
|
| Tissue and Organ Procurement | 1 | 2000 | 388 | 0.120 |
Why?
|
| Hyperoxia | 1 | 2016 | 37 | 0.120 |
Why?
|
| Adolescent | 6 | 2023 | 9878 | 0.120 |
Why?
|
| Aging | 1 | 2020 | 766 | 0.120 |
Why?
|
| Thrombosis | 1 | 2018 | 326 | 0.120 |
Why?
|
| Ureaplasma | 1 | 2015 | 5 | 0.110 |
Why?
|
| Cell Separation | 1 | 2016 | 205 | 0.110 |
Why?
|
| Ureaplasma Infections | 1 | 2015 | 4 | 0.110 |
Why?
|
| Immunophenotyping | 1 | 2016 | 226 | 0.110 |
Why?
|
| Hyperammonemia | 1 | 2015 | 14 | 0.110 |
Why?
|
| Societies, Medical | 1 | 2018 | 645 | 0.110 |
Why?
|
| Length of Stay | 3 | 2007 | 835 | 0.110 |
Why?
|
| Anaphylatoxins | 1 | 2014 | 1 | 0.110 |
Why?
|
| Mitochondria | 1 | 2018 | 621 | 0.110 |
Why?
|
| Receptors, Prostaglandin E, EP4 Subtype | 1 | 2014 | 5 | 0.110 |
Why?
|
| Intramolecular Oxidoreductases | 1 | 2014 | 8 | 0.110 |
Why?
|
| Longitudinal Studies | 2 | 2012 | 1176 | 0.100 |
Why?
|
| Flow Cytometry | 1 | 2016 | 725 | 0.100 |
Why?
|
| Solubility | 1 | 2014 | 190 | 0.100 |
Why?
|
| ets-Domain Protein Elk-1 | 1 | 2013 | 8 | 0.100 |
Why?
|
| Treatment Outcome | 5 | 2014 | 9228 | 0.100 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2015 | 396 | 0.100 |
Why?
|
| Antibodies, Monoclonal | 3 | 2007 | 1425 | 0.100 |
Why?
|
| Genetic Markers | 3 | 2021 | 477 | 0.100 |
Why?
|
| Transcriptome | 1 | 2019 | 766 | 0.100 |
Why?
|
| Surveys and Questionnaires | 3 | 2022 | 2860 | 0.100 |
Why?
|
| Anti-Bacterial Agents | 1 | 1999 | 848 | 0.100 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2018 | 890 | 0.100 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2013 | 126 | 0.100 |
Why?
|
| Angiopoietin-2 | 1 | 2012 | 21 | 0.100 |
Why?
|
| DNA, Viral | 3 | 2002 | 272 | 0.100 |
Why?
|
| MAP Kinase Signaling System | 1 | 2013 | 206 | 0.090 |
Why?
|
| Young Adult | 5 | 2023 | 7034 | 0.090 |
Why?
|
| Pathology, Clinical | 1 | 2012 | 39 | 0.090 |
Why?
|
| ROC Curve | 2 | 2014 | 799 | 0.090 |
Why?
|
| Cytokines | 2 | 2018 | 871 | 0.090 |
Why?
|
| Pulmonary Medicine | 1 | 2012 | 51 | 0.090 |
Why?
|
| Lung Injury | 1 | 2012 | 60 | 0.090 |
Why?
|
| Quantitative Trait Loci | 1 | 2015 | 632 | 0.090 |
Why?
|
| Observer Variation | 1 | 2013 | 626 | 0.090 |
Why?
|
| T-Lymphocytes, Regulatory | 2 | 2014 | 342 | 0.090 |
Why?
|
| Hemodynamics | 3 | 2000 | 776 | 0.090 |
Why?
|
| Pulmonary Surfactant-Associated Protein D | 1 | 2011 | 7 | 0.090 |
Why?
|
| Drug Resistance, Microbial | 2 | 2002 | 72 | 0.080 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2021 | 2777 | 0.080 |
Why?
|
| Antibodies, Monoclonal, Humanized | 3 | 2007 | 1021 | 0.080 |
Why?
|
| Endothelial Cells | 1 | 2013 | 477 | 0.080 |
Why?
|
| Genetic Variation | 2 | 2015 | 1424 | 0.080 |
Why?
|
| Cyclosporine | 1 | 2011 | 242 | 0.080 |
Why?
|
| Cell Differentiation | 3 | 2017 | 1662 | 0.080 |
Why?
|
| Prednisone | 1 | 2010 | 252 | 0.080 |
Why?
|
| Risk Assessment | 4 | 2018 | 2498 | 0.080 |
Why?
|
| Receptors, Interleukin-2 | 2 | 2007 | 69 | 0.070 |
Why?
|
| Polymerase Chain Reaction | 3 | 2015 | 930 | 0.070 |
Why?
|
| Obesity | 2 | 2017 | 1029 | 0.070 |
Why?
|
| Microbial Sensitivity Tests | 2 | 2015 | 153 | 0.070 |
Why?
|
| Patient Readmission | 2 | 2010 | 413 | 0.070 |
Why?
|
| Transplantation Tolerance | 1 | 2010 | 143 | 0.070 |
Why?
|
| Serum Response Factor | 1 | 2009 | 46 | 0.070 |
Why?
|
| Illinois | 2 | 2001 | 530 | 0.070 |
Why?
|
| Immunoassay | 1 | 2008 | 100 | 0.070 |
Why?
|
| Severity of Illness Index | 4 | 2018 | 1982 | 0.070 |
Why?
|
| Statistics, Nonparametric | 2 | 2012 | 311 | 0.070 |
Why?
|
| Signal Transduction | 1 | 2018 | 3581 | 0.070 |
Why?
|
| Genotype | 4 | 2015 | 1883 | 0.070 |
Why?
|
| United States Food and Drug Administration | 1 | 2008 | 147 | 0.070 |
Why?
|
| Salvage Therapy | 1 | 2009 | 238 | 0.070 |
Why?
|
| Fibrosis | 2 | 2020 | 235 | 0.070 |
Why?
|
| Reproducibility of Results | 3 | 2021 | 2885 | 0.070 |
Why?
|
| Adenosine Triphosphate | 1 | 2008 | 329 | 0.070 |
Why?
|
| Cell Proliferation | 1 | 2013 | 1753 | 0.060 |
Why?
|
| Immunity | 1 | 2008 | 155 | 0.060 |
Why?
|
| Registries | 2 | 2024 | 998 | 0.060 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2012 | 647 | 0.060 |
Why?
|
| Critical Pathways | 1 | 2007 | 36 | 0.060 |
Why?
|
| Animals | 8 | 2019 | 28901 | 0.060 |
Why?
|
| Sensitivity and Specificity | 2 | 2021 | 2042 | 0.060 |
Why?
|
| Transforming Growth Factor beta | 1 | 2009 | 349 | 0.060 |
Why?
|
| Photopheresis | 2 | 2011 | 12 | 0.060 |
Why?
|
| Phenotype | 4 | 2016 | 2575 | 0.060 |
Why?
|
| Chemokines, CXC | 1 | 2006 | 22 | 0.060 |
Why?
|
| Disease Progression | 1 | 2010 | 1561 | 0.060 |
Why?
|
| Multigene Family | 1 | 2006 | 213 | 0.060 |
Why?
|
| Fibroblasts | 1 | 2009 | 776 | 0.060 |
Why?
|
| Genome, Viral | 1 | 2006 | 80 | 0.060 |
Why?
|
| Mice | 5 | 2018 | 12525 | 0.060 |
Why?
|
| Kidney | 2 | 2024 | 1135 | 0.060 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2008 | 487 | 0.060 |
Why?
|
| Kidney Function Tests | 1 | 2025 | 116 | 0.060 |
Why?
|
| Disease Models, Animal | 3 | 2019 | 2534 | 0.060 |
Why?
|
| Hyperlipidemias | 1 | 2005 | 91 | 0.050 |
Why?
|
| Safety | 1 | 2005 | 147 | 0.050 |
Why?
|
| Viral Proteins | 1 | 2006 | 289 | 0.050 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2006 | 701 | 0.050 |
Why?
|
| Glomerular Filtration Rate | 1 | 2025 | 281 | 0.050 |
Why?
|
| Intubation, Intratracheal | 2 | 2007 | 161 | 0.050 |
Why?
|
| Survival Analysis | 2 | 2011 | 1541 | 0.050 |
Why?
|
| Linear Models | 2 | 2017 | 438 | 0.050 |
Why?
|
| Proportional Hazards Models | 2 | 2018 | 905 | 0.050 |
Why?
|
| Creatinine | 1 | 2024 | 299 | 0.050 |
Why?
|
| Lipids | 1 | 2005 | 285 | 0.050 |
Why?
|
| Drug Administration Schedule | 1 | 2004 | 857 | 0.050 |
Why?
|
| Drug Resistance, Viral | 1 | 2002 | 48 | 0.050 |
Why?
|
| RNA | 1 | 2006 | 603 | 0.050 |
Why?
|
| Waiting Lists | 2 | 2006 | 212 | 0.050 |
Why?
|
| Gene Expression Regulation | 2 | 2011 | 2059 | 0.050 |
Why?
|
| Administration, Inhalation | 2 | 2000 | 203 | 0.040 |
Why?
|
| Probability | 1 | 2002 | 365 | 0.040 |
Why?
|
| Cell Line | 2 | 2018 | 2536 | 0.040 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 2001 | 39 | 0.040 |
Why?
|
| Genetic Association Studies | 2 | 2014 | 301 | 0.040 |
Why?
|
| Immunization, Passive | 1 | 2001 | 75 | 0.040 |
Why?
|
| Reference Values | 1 | 2002 | 675 | 0.040 |
Why?
|
| Contraindications | 1 | 2021 | 70 | 0.040 |
Why?
|
| Body Mass Index | 2 | 2017 | 816 | 0.040 |
Why?
|
| Organophosphorus Compounds | 1 | 2001 | 52 | 0.040 |
Why?
|
| Antiviral Agents | 2 | 2002 | 504 | 0.040 |
Why?
|
| Morbidity | 1 | 2021 | 162 | 0.040 |
Why?
|
| Marijuana Smoking | 1 | 2000 | 28 | 0.040 |
Why?
|
| Surgical Wound Dehiscence | 1 | 2000 | 38 | 0.040 |
Why?
|
| Cytosine | 1 | 2001 | 135 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2004 | 935 | 0.040 |
Why?
|
| Cell Culture Techniques | 1 | 2001 | 197 | 0.040 |
Why?
|
| Inflammation | 1 | 2006 | 1063 | 0.040 |
Why?
|
| Pulmonary Gas Exchange | 1 | 2000 | 36 | 0.040 |
Why?
|
| Cocaine-Related Disorders | 1 | 2000 | 41 | 0.040 |
Why?
|
| Odds Ratio | 2 | 2012 | 721 | 0.040 |
Why?
|
| Chi-Square Distribution | 1 | 2000 | 365 | 0.040 |
Why?
|
| Blood Loss, Surgical | 1 | 2000 | 133 | 0.040 |
Why?
|
| Cardiopulmonary Bypass | 1 | 2000 | 162 | 0.040 |
Why?
|
| Evidence-Based Medicine | 2 | 2012 | 458 | 0.040 |
Why?
|
| Global Health | 1 | 2021 | 214 | 0.040 |
Why?
|
| Genetic Testing | 1 | 2023 | 566 | 0.040 |
Why?
|
| Collagen Type V | 1 | 2019 | 3 | 0.040 |
Why?
|
| Chromosome Mapping | 1 | 2022 | 1080 | 0.040 |
Why?
|
| Intraoperative Complications | 1 | 2000 | 197 | 0.040 |
Why?
|
| Tubulin | 1 | 2019 | 61 | 0.040 |
Why?
|
| Collagen Type I | 1 | 2019 | 74 | 0.040 |
Why?
|
| Pneumonia | 1 | 2000 | 196 | 0.040 |
Why?
|
| Heart-Lung Transplantation | 1 | 1999 | 20 | 0.040 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2000 | 233 | 0.040 |
Why?
|
| Electron Transport | 1 | 2018 | 74 | 0.040 |
Why?
|
| Respiratory Function Tests | 1 | 1999 | 157 | 0.040 |
Why?
|
| Organ Specificity | 1 | 2019 | 285 | 0.030 |
Why?
|
| Hospitals, University | 1 | 1999 | 199 | 0.030 |
Why?
|
| Autoantigens | 1 | 2019 | 139 | 0.030 |
Why?
|
| Tissue and Organ Harvesting | 1 | 1999 | 83 | 0.030 |
Why?
|
| Rectum | 1 | 1999 | 151 | 0.030 |
Why?
|
| Health Care Rationing | 1 | 2018 | 85 | 0.030 |
Why?
|
| Communicable Diseases | 1 | 1999 | 69 | 0.030 |
Why?
|
| Reoperation | 1 | 2000 | 712 | 0.030 |
Why?
|
| Autoimmunity | 1 | 2019 | 191 | 0.030 |
Why?
|
| Respiratory Insufficiency | 1 | 2000 | 205 | 0.030 |
Why?
|
| Asbestos | 1 | 2017 | 22 | 0.030 |
Why?
|
| Interleukin-6 | 1 | 2018 | 281 | 0.030 |
Why?
|
| A549 Cells | 1 | 2017 | 51 | 0.030 |
Why?
|
| Critical Care | 1 | 2000 | 448 | 0.030 |
Why?
|
| Bleomycin | 1 | 2017 | 101 | 0.030 |
Why?
|
| Oxidants | 1 | 2017 | 86 | 0.030 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2017 | 113 | 0.030 |
Why?
|
| Age Factors | 1 | 2000 | 1959 | 0.030 |
Why?
|
| Monocytes | 1 | 2017 | 219 | 0.030 |
Why?
|
| Lipid Peroxidation | 1 | 2016 | 47 | 0.030 |
Why?
|
| Consensus | 1 | 2018 | 372 | 0.030 |
Why?
|
| Reactive Oxygen Species | 1 | 2018 | 516 | 0.030 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 2015 | 46 | 0.030 |
Why?
|
| Ammonia | 1 | 2015 | 45 | 0.030 |
Why?
|
| Intensive Care Units | 1 | 1999 | 460 | 0.030 |
Why?
|
| DNA Damage | 1 | 2017 | 392 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 1999 | 1966 | 0.030 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2015 | 84 | 0.030 |
Why?
|
| Spirometry | 1 | 2014 | 78 | 0.030 |
Why?
|
| Prostaglandin-E Synthases | 1 | 2014 | 3 | 0.030 |
Why?
|
| Immunocompromised Host | 1 | 2015 | 147 | 0.030 |
Why?
|
| Carbon Dioxide | 1 | 2015 | 213 | 0.030 |
Why?
|
| Species Specificity | 1 | 2016 | 708 | 0.030 |
Why?
|
| Dinoprostone | 1 | 2014 | 75 | 0.030 |
Why?
|
| Genotyping Techniques | 1 | 2014 | 71 | 0.030 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2013 | 68 | 0.030 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2013 | 76 | 0.020 |
Why?
|
| Adaptor Proteins, Vesicular Transport | 1 | 2013 | 52 | 0.020 |
Why?
|
| Granzymes | 1 | 2013 | 96 | 0.020 |
Why?
|
| Proteolysis | 1 | 2013 | 124 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2012 | 221 | 0.020 |
Why?
|
| Resistin | 1 | 2011 | 12 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2017 | 2160 | 0.020 |
Why?
|
| Adiponectin | 1 | 2011 | 21 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 2013 | 750 | 0.020 |
Why?
|
| Graft Enhancement, Immunologic | 1 | 2011 | 13 | 0.020 |
Why?
|
| Preoperative Care | 1 | 2014 | 419 | 0.020 |
Why?
|
| Leptin | 1 | 2011 | 102 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2018 | 3483 | 0.020 |
Why?
|
| Familial Primary Pulmonary Hypertension | 1 | 2011 | 65 | 0.020 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2011 | 89 | 0.020 |
Why?
|
| Overweight | 1 | 2011 | 121 | 0.020 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2011 | 106 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2013 | 1018 | 0.020 |
Why?
|
| Computational Biology | 1 | 2014 | 587 | 0.020 |
Why?
|
| Haplotypes | 1 | 2012 | 652 | 0.020 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2011 | 190 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2011 | 380 | 0.020 |
Why?
|
| Cystic Fibrosis | 1 | 2011 | 121 | 0.020 |
Why?
|
| Smad Proteins | 1 | 2009 | 44 | 0.020 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 1 | 2009 | 112 | 0.020 |
Why?
|
| Heart Failure | 1 | 1999 | 1438 | 0.020 |
Why?
|
| Gene Knockdown Techniques | 1 | 2009 | 256 | 0.020 |
Why?
|
| Cyclic AMP | 1 | 2009 | 283 | 0.020 |
Why?
|
| Immunity, Innate | 1 | 2011 | 464 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2009 | 562 | 0.020 |
Why?
|
| Actins | 1 | 2009 | 472 | 0.010 |
Why?
|
| Open Reading Frames | 1 | 2006 | 124 | 0.010 |
Why?
|
| Glycosylation | 1 | 2006 | 137 | 0.010 |
Why?
|
| Genomic Instability | 1 | 2006 | 88 | 0.010 |
Why?
|
| Practice Guidelines as Topic | 1 | 2012 | 1096 | 0.010 |
Why?
|
| History, 21st Century | 1 | 2006 | 192 | 0.010 |
Why?
|
| History, 20th Century | 1 | 2006 | 327 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2006 | 897 | 0.010 |
Why?
|
| Patient Discharge | 1 | 2007 | 363 | 0.010 |
Why?
|
| Genes, Viral | 1 | 2002 | 109 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2006 | 2090 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2006 | 3040 | 0.010 |
Why?
|
| Hospitalization | 1 | 2007 | 946 | 0.010 |
Why?
|
| Shock | 1 | 2000 | 47 | 0.010 |
Why?
|
| Antibodies | 1 | 2001 | 356 | 0.010 |
Why?
|
| Chronic Disease | 1 | 2000 | 983 | 0.010 |
Why?
|
| Hypoxia | 1 | 2000 | 681 | 0.010 |
Why?
|
| Child | 1 | 2006 | 7621 | 0.010 |
Why?
|
| Mutation | 1 | 2002 | 4374 | 0.010 |
Why?
|